On Tuesday, Evercore ISI maintained a positive outlook on Domino's Pizza (NASDAQ:DPZ) shares, reiterating an Outperform rating and a $480.00 price target. Currently trading at $455.64, the stock ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investing.com-- Evercore analysts expect a sizable revenue bump from Apple Inc’s (NASDAQ:AAPL) recently unveiled iPhone 16e and also lauded the company’s new modem chip, both of which they expect to ...

Investing.com-- Evercore analysts expect a sizable revenue bump from Apple Inc's (NASDAQ:AAPL) recently unveiled iPhone 16e and also lauded the company’s new modem chip, both of which they ...

Evercore ISI added Lowe’s (LOW) to the firm’s “Tactical Outperform List” while keeping an In Line rating on the shares with a $290 price target into the Q4 report. Reaffirming guidance ...

We’re dropping our coverage of Evercore. Morningstar provides research on approximately 1,500 publicly traded stocks, and we periodically revise our lists in response to client interest and ...

However, Vela Games has decided it would rather not wait and launched a demo for their revamped co-op rogue-like Evercore Heroes: Ascension today. Anyone who would like to give the title a go can do ...

Intel Apollo Joint Venture/Intel Corporation Nataraj, who has been at Evercore since 2002, is a member of the firm's management committee and a top banker in its technology, media, and ...

Specialty MGA Optio Group has retained investment bank Evercore with a mandate to explore its debt options, as the business looks to ensure it has adequate dry powder to pursue its M&A strategy ...

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (BRSE:1CG) from In-Line to Outperform. There are 577 funds or institutions reporting ...

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from In-Line to Outperform. Analyst Price Forecast Suggests 90.46% ...